Literature DB >> 17292579

Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era.

Robert C Owens1, Paul G Ambrose.   

Abstract

Antimicrobial stewardship, a term coined by Dale Gerding, is defined as the optimal selection, dose, and duration of an antimicrobial that results in the best clinical outcome for the treatment or prevention of infection, with minimal toxicity to the patient and minimal impact on subsequent resistance development. Methods to promote and ensure good antimicrobial stewardship have been implemented and studied, and have typically provided tangible benefits in terms of a reduction in overall or targeted antimicrobial usage and resistance emergence. Although most of the programmatic antimicrobial stewardship efforts have been conducted in acute care inpatient settings, some strategies usually involving education have been evaluated in the outpatient venue. In this review, we shall discuss issues related to why antimicrobial stewardship is of particular importance in the modern antibiotic era. In addition, general pharmacokinetic-pharmacodynamic (PK-PD) concepts will be reviewed and specific PK-PD analyses that support the optimal selection, dosing, and duration of therapy for beta-lactam antimicrobials will be provided.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17292579     DOI: 10.1016/j.diagmicrobio.2006.12.012

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  12 in total

1.  Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.

Authors:  Jennifer Hoover; Thomas Lewandowski; Robert J Straub; Steven J Novick; Peter DeMarsh; Kelly Aubart; Stephen Rittenhouse; Magdalena Zalacain
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

2.  Pharmacokinetics of Ceftiofur Crystalline-Free Acid in Clinically Healthy Dogs (Canis lupus familiaris).

Authors:  Sarah E Hooper; Scott W Korte; Steeve Giguère; William H Fales; Jennifer L Davis; Lonny W Dixon
Journal:  J Am Assoc Lab Anim Sci       Date:  2016-03       Impact factor: 1.232

3.  Evaluation of cefotaxime and desacetylcefotaxime concentrations in cord blood after intrapartum prophylaxis with cefotaxime.

Authors:  Jacques Lepercq; Jean Marc Treluyer; Christelle Auger; Josette Raymond; Elisabeth Rey; Thomas Schmitz; Vincent Jullien
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

4.  Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle.

Authors:  Ijaz Ahmad; Haihong Hao; Lingli Huang; Pascal Sanders; Xu Wang; Dongmei Chen; Yanfei Tao; Shuyu Xie; Kuang Xiuhua; Juan Li; Wan Dan; Zonghui Yuan
Journal:  Front Microbiol       Date:  2015-06-17       Impact factor: 5.640

5.  Towards a global definition of responsible antibiotic use: results of an international multidisciplinary consensus procedure.

Authors:  Annelie A Monnier; Barry I Eisenstein; Marlies E Hulscher; Inge C Gyssens
Journal:  J Antimicrob Chemother       Date:  2018-06-01       Impact factor: 5.790

Review 6.  Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association.

Authors:  Bin Cao; Yi Huang; Dan-Yang She; Qi-Jian Cheng; Hong Fan; Xin-Lun Tian; Jin-Fu Xu; Jing Zhang; Yu Chen; Ning Shen; Hui Wang; Mei Jiang; Xiang-Yan Zhang; Yi Shi; Bei He; Li-Xian He; You-Ning Liu; Jie-Ming Qu
Journal:  Clin Respir J       Date:  2017-09-26       Impact factor: 2.570

Review 7.  An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?

Authors:  Robert C Owens
Journal:  Crit Care       Date:  2008-05-21       Impact factor: 9.097

8.  The Epidemiologic and Pharmacodynamic Cutoff Values of Tilmicosin against Haemophilus parasuis.

Authors:  Peng Zhang; Haihong Hao; Jun Li; Ijaz Ahmad; Guyue Cheng; Dongmei Chen; Yanfei Tao; Lingli Huang; Yulian Wang; Menghong Dai; Zhenli Liu; Zonghui Yuan
Journal:  Front Microbiol       Date:  2016-03-22       Impact factor: 5.640

9.  The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin against Haemophilus parasuis.

Authors:  Zhixin Lei; Qianying Liu; Bing Yang; Saeed Ahmed; Jiyue Cao; Qigai He
Journal:  Oncotarget       Date:  2017-12-07

10.  Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.

Authors:  Yongda Zhao; Li-Li Guo; Binghu Fang; Baotao Liu
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.